SCHEMBL4520346

SCHEMBL4520346

C[C@@H](COc1cccc2ncccc12)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 9/20 0.67
CACNA2D1 P54289 2/20 0.48
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TP53 P04637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
S1PR4 O95977 1/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
S1PR1 P21453 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NFKBIA P25963 1/20 0.43
RELA Q04206 1/20 0.43
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501569 0.84 NR3C1 (0.68) NR3C1CACNA2D1MEN1KMT2ATP53
SCHEMBL4518089 0.83 NR3C1 (0.67) NR3C1CACNA2D1MEN1KMT2ATP53
SCHEMBL4513381 0.82 NR3C1 (0.64) NR3C1MEN1KMT2ATP53LMNA
SCHEMBL4516700 0.81 NR3C1 (0.62) NR3C1CACNA2D1MEN1KMT2ATP53
SCHEMBL4501700 0.80 NR3C1 (1.00) NR3C1
SCHEMBL4521905 0.80 NR3C1 (0.74) NR3C1CACNA2D1SMN1; SMN2
SCHEMBL4517669 0.78 NR3C1 (0.73) NR3C1ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL4513347 0.77 NR3C1 (0.55) NR3C1MEN1KMT2ATP53ALDH1A1
SCHEMBL4519953 0.77 NR3C1 (1.00) NR3C1
SCHEMBL4515242 0.77 NR3C1 (0.69) NR3C1CACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885CACNA2D1 3173/4885MEN1 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.